Pub. Date : 2015 Jul-Aug
PMID : 25983101
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |
| 2 | ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |
| 3 | Furthermore, overexpression of ANXA1 induced by ATO resulted in activation of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (MAPKs), rendering cancer cells resistant to the agent. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |
| 4 | Furthermore, overexpression of ANXA1 induced by ATO resulted in activation of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (MAPKs), rendering cancer cells resistant to the agent. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |
| 5 | In addition, PD98059, a specific ERK inhibitor, increased the sensitivity of cancer cells to a lower concentration of ATO treatment. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |
| 6 | CONCLUSIONS: Taken together, these data indicate that overexpression of ANXA1 induced by low-concentration ATO makes cancer cells more resistant to the agent via activated ERK MAPKs. | Arsenic Trioxide | mitogen-activated protein kinase 1 | Homo sapiens |